TRINETRA › Sectors › Healthcare
Procter & Gamble Health Limited (PGHL) — share price, P/E and fundamentals
Procter & Gamble Health Limited (NSE: PGHL) closed at ₹5,699.50 on 30 Oct 2026, -8.7% over one year, against a 52-week range of ₹4,707.00 – ₹6,975.00.
In the quarter ended 30 Jun 2026 (standalone, filed 6 Aug 2026) it reported revenue of ₹364 cr and net profit of ₹96 cr, a 26.4% net margin; revenue grew 7.4% and profit grew 45.4% year on year.
On four consecutive filed quarters its trailing P/E is 26.5; since 17 Jun 2025 its own P/E has ranged from 23.3 to 46.6 (median 37.5), and today's reading is higher than 11% of those 338 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 73.3%, ROCE 88.2%, debt-to-equity 0.00, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 89% of 63 sector peers; PBT margin higher than 92% of 63 sector peers; ROE higher than 100% of 63 sector peers.
Key figures
| Last close | ₹5,699.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +5.2% / +10.9% / -8.7% |
| 52-week low – high | ₹4,707.00 – ₹6,975.00 |
| Market capitalisation | ₹9,461 cr |
| Trailing P/E | 26.5 |
| Price / book | 18.04 |
| EV / EBITDA | 18.0 |
| Earnings yield | 3.8% |
| TTM EPS | ₹214.99 |
| TTM net profit | ₹357 cr |
| Quarter revenue | ₹364 cr |
| Quarter net profit | ₹96 cr |
| Net margin | 26.4% |
| Revenue growth (YoY) | +7.4% |
| Profit growth (YoY) | +45.4% |
| Return on equity | 73.3% |
| ROCE | 88.2% |
| Debt / equity | 0.00 |
| Current ratio | 2.18 |
| Free cash flow | ₹322 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹4.7 cr |
Against Healthcare peers
| Metric | PGHL | Peer median | Percentile |
|---|---|---|---|
| Net margin | 26.44 | 12.67 | 89 |
| PBT margin | 35.50 | 17.57 | 92 |
| ROE | 73.32 | 13.86 | 100 |
| ROCE | 88.17 | 16.59 | 100 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 1.03 | 1.25 | 36 |
| Trailing P/E | 26.51 | 43.26 | 17 |
| P/B | 18.04 | 5.88 | 95 |
Questions
What is the P/E ratio of Procter & Gamble Health Limited?
Procter & Gamble Health Limited's trailing P/E is 26.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 17 Jun 2025 its P/E has ranged 23.3–46.6.
What were Procter & Gamble Health Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Procter & Gamble Health Limited reported revenue of ₹364 cr and net profit of ₹96 cr (standalone), filed with the exchange on 6 Aug 2026.
What is Procter & Gamble Health Limited's ROE?
Return on equity is 73.3% based on the balance sheet dated 31 Mar 2026.
Does Procter & Gamble Health Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is PGHL's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, PGHL traded between ₹4,707.00 and ₹6,975.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.